Joseph Miller is a distinguished finance executive with more than 25 years of experience in the pharmaceutical and biotechnology sectors. His career began in public accounting at Ernst & Young, where he honed his expertise in financial reporting and auditing for life sciences companies. Miller later advanced to senior roles at Valeant Pharmaceuticals International (now Bausch Health), serving as Senior Vice President of Finance, where he spearheaded financial strategies during complex mergers, acquisitions, and restructurings, contributing to the company's expansion into global markets. As Chief Financial Officer at Aurinia Pharmaceuticals Inc. from 2017 to 2021, Miller played a pivotal role in steering the company's financial trajectory during a critical growth phase. He orchestrated multiple equity financings raising over $500 million, which funded the late-stage development and eventual FDA approval of Lupkynis (voclosporin), Aurinia's breakthrough therapy for lupus nephritis. Under his leadership, Aurinia strengthened its balance sheet, enhanced investor relations, and navigated SEC compliance amid rapid commercialization efforts. Miller's strategic acumen and deep industry knowledge have earned him recognition for driving sustainable financial health in innovative biopharma environments, positioning Aurinia for long-term success in autoimmune disease treatments.